ChemicalBook
Chinese english Germany Japanese Korea

4,4'-Diaminodiphenylsulfon Produkt Beschreibung

4,4'-Diaminodiphenylsulfone Struktur
80-08-0
CAS-Nr.
80-08-0
Bezeichnung:
4,4'-Diaminodiphenylsulfon
Englisch Name:
4,4'-Diaminodiphenylsulfone
Synonyma:
DDS;K509;wr448;DADPS;1358F;f1358;DADDS;Udolac;WR 448;EPORAL
CBNumber:
CB0152851
Summenformel:
C12H12N2O2S
Molgewicht:
248.3
MOL-Datei:
80-08-0.mol

4,4'-Diaminodiphenylsulfon Eigenschaften

Schmelzpunkt:
175-177 °C(lit.)
Dichte
1.2701 (rough estimate)
Brechungsindex
1.5950 (estimate)
storage temp. 
-20°C Freezer
Löslichkeit
0.38g/l
Aggregatzustand
Crystalline Powder
pka
pKb 13.0(at 25℃)
Farbe
White to beige
PH
5.5-7.5 (H2O, 20℃)(saturated aqueous solution)
Wasserlöslichkeit
<0.1 g/100 mL at 20 ºC
Merck 
14,2822
BRN 
788055
Stabilität:
Stable. Combustible. Incompatible with strong oxidizing agents.
InChIKey
MQJKPEGWNLWLTK-UHFFFAOYSA-N
CAS Datenbank
80-08-0(CAS DataBase Reference)
NIST chemische Informationen
Dapsone(80-08-0)
EPA chemische Informationen
Benzenamine, 4,4'-sulfonylbis-(80-08-0)
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Kennzeichnung gefährlicher Xn
R-Sätze: 22
S-Sätze: 22
RIDADR  3249
WGK Germany  1
RTECS-Nr. BY8925000
TSCA  Yes
HazardClass  6.1(b)
PackingGroup  III
HS Code  29051620
HS Code  29309070
Giftige Stoffe Daten 80-08-0(Hazardous Substances Data)
Toxizität LD50 orally in Rabbit: 1000 mg/kg LD50 dermal Rabbit > 4000 mg/kg
Bildanzeige (GHS)
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H302 Gesundheitsschädlich bei Verschlucken. Akute Toxizität oral Kategorie 4 Warnung P264, P270, P301+P312, P330, P501
H320 Causes eye irritation Serious eye damage/eye irritation Category 2B Warnung P264, P305+P351+P338,P337+P313
H370 Schädigt die Organe. Spezifische Zielorgan-Toxizität (einmalige Exposition) Kategorie 1 Achtung P260, P264, P270, P307+P311, P321,P405, P501
H372 Schädigt bei Hautkontakt und Verschlucken die Organe bei längerer oder wiederholter Exposition. Spezifische Zielorgan-Toxizität (wiederholte Exposition) Kategorie 1 Achtung P260, P264, P270, P314, P501
Sicherheit
P260 Dampf/Aerosol/Nebel nicht einatmen.
P261 Einatmen von Staub vermeiden.
P264 Nach Gebrauch gründlich waschen.
P264 Nach Gebrauch gründlich waschen.
P270 Bei Gebrauch nicht essen, trinken oder rauchen.
P307+P311 BEI Exposition: GIFTINFORMATIONSZENTRUM oder Arzt anrufen.
P405 Unter Verschluss aufbewahren.
P501 Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen.

4,4'-Diaminodiphenylsulfon Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:

R22:Gesundheitsschädlich beim Verschlucken.

S-Sätze Betriebsanweisung:

S22:Staub nicht einatmen.

Chemische Eigenschaften

Off -White Crystalline Solid

Verwenden

An antibacterial used in the treatment of dermatitis herpetiformis

Verwenden

antibacterial, leprostatic, dermatitis herpetiformis suppressant

Verwenden

4,4'-diaminodiphenylsulfone be used for preparation polyimide and epoxy resin material.

Verwenden

Hardening agent in the curing of epoxy resins.

Definition

ChEBI: A sulfone that is diphenylsulfone in which the hydrogen atom at the 4 position of each of the phenyl groups is substituted by an amino group. It is active against a wide range of bacteria, but is mainly employed for its actions against Mycobacteriu leprae, being used as part of multidrug regimens in the treatment of all forms of leprosy.

Indications

Although dapsone (Avlosulfon) is most often used as an antimicrobial agent, it has important antiinflammatory properties in many noninfectious skin diseases. The mechanism of action of dapsone in skin disease is not clear.Most of the cutaneous diseases for which it is effective manifest inflammation and are characterized by an infiltration of neutrophils; the drug’s antiinflammatory effect may arise from its inhibition of intracellular neutrophil reactions mediated by myeloperoxidase and hydrogen peroxide or from its scavenging of reactive oxygen species, which inhibits inflammation.

Indications

Although dapsone (Avlosulfon) was once used in the treatment and prophylaxis of chloroquine-resistant P. falciparum malaria, the toxicities associated with its administration (e.g., agranulocytosis, methemoglobinemia, hemolytic anemia) have severely reduced its use. Occasionally dapsone has been added to the usual chloroquine therapeutic regimen for the prophylaxis of chloroquine-resistant P. falciparum malaria. It is also used in combination therapy for leprosy.

Trademarks

Hansolar (ParkeDavis).

Antimicrobial activity

Dapsone is active against many bacteria and some protozoa. Fully susceptible strains of M. leprae are inhibited by a little as 0.003 mg/L. It is predominantly bacteristatic. Resistance is associated with mutations in the folP1 gene involved in the synthesis of para-aminobenzoic acid.

Acquired resistance

Resistance to high levels is acquired by several sequential mutations. As a result of prolonged use of dapsone monotherapy, acquired resistance emerged in patients with multibacillary leprosy in many countries. Initial resistance also occurs in patients with both paucibacillary and multibacillary leprosy. Thus, leprosy should always be treated with multidrug regimens. Resistance of M. leprae to dapsone (and other anti-leprosy drugs) may now be determined by use of DNA microarrays.

Allgemeine Beschreibung

Odorless white or creamy white crystalline powder. Slightly bitter taste.

Air & Water Reaktionen

Sensitive to oxidation and light. Insoluble in water.

Reaktivität anzeigen

4,4'-Diaminodiphenylsulfone can neutralize acids in exothermic reactions to form salts plus water. May be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen is generated in combination with strong reducing agents, such as hydrides. Incompatible with strong oxidizing agents. Also incompatible with epoxy resins under uncontrolled conditions .

Brandgefahr

4,4'-Diaminodiphenylsulfone is probably combustible.

Pharmazeutische Anwendungen

The most effective of a number of sulfonamide derivatives to be tested against leprosy. The dry powder is very stable. It is only slightly soluble in water.

Pharmakokinetik

Oral absorption: >90%
Cmax 100 mg oral: c. 2 mg/L after 3–6 h
Plasma half-life: 10–50 h
Plasma protein binding: c. 50%
It is slowly but almost completely absorbed from the intestine and widely distributed in the tissues, but selectively retained in skin, muscle, kidneys and liver. It is metabolized by N-oxidation and also by acetylation, which is subject to the same genetic polymorphism as isoniazid. The elimination half-life is consequently very variable, but on standard therapy the trough levels are always well in excess of inhibitory concentrations. It is mostly excreted in the urine: in the unchanged form (20%), as N-oxidation products (30%) and as a range of other metabolites.

Clinical Use

Dapsone (4,4 -sulfonylbisbenzeneamine; 4,4 -sulfonyldianiline;p,p -diaminodiphenylsulfone; or DDS [Avlosulfon])occurs as an odorless, white crystalline powder that is veryslightly soluble in water and sparingly soluble in alcohol.The pure compound is light stable, but traces of impurities,including water, make it photosensitive and thus susceptibleto discoloration in light. Although no chemical change is detectablefollowing discoloration, the drug should be protectedfrom light.
Dapsone is used in the treatment of both lepromatous andtuberculoid types of leprosy. Dapsone is used widely for allforms of leprosy, often in combination with clofazimine andrifampin. Initial treatment often includes rifampin with dapsone,followed by dapsone alone. It is also used to preventthe occurrence of multibacillary leprosy when given prophylactically.Dapsone is also the drug of choice for dermatitis herpetiformisand is sometimes used with pyrimethamine for treatmentof malaria and with trimethoprim for PCP.
Serious side effects can include hemolytic anemia,methemoglobinemia, and toxic hepatic effects. Hemolyticeffects can be pronounced in patients with glucose-6-phosphatedehydrogenase deficiency. During therapy, all patientsrequire frequent blood counts.

Clinical Use

Dapsone is approved for the treatment of an autoimmune blistering skin disease, dermatitis herpetiformis. This intensely pruritic eruption is characterized histologically by a dense dermal infiltration of neutrophils and subepidermal blisters. Other skin diseases in which dapsone is helpful are linear immunoglobulin A (IgA) dermatosis, subcorneal pustular dermatosis, leukocytoclastic vasculitis, and a variety of rarer eruptions in which neutrophils predominate, including some forms of cutaneous lupus erythematosus.

Clinical Use

Leprosy (multidrug regimens)
Prophylaxis of malaria, treatment of chloroquine-resistant malaria (in combination with pyrimethamine)
Prophylaxis of toxoplasmosis (in combination with pyrimethamine)
Prophylaxis (monotherapy) and treatment (in combination with trimethoprim) of Pneumocystis jirovecii pneumonia
Dermatitis herpetiformis and related skin disorders

Nebenwirkungen

Although usually well tolerated at standard doses, gastrointestinal upsets, anorexia, headaches, dizziness and insomnia may occur. Less frequent reactions include skin rashes, exfoliative dermatitis, photosensitivity, peripheral neuropathy (usually in non-leprosy patients), tinnitus, blurred vision, psychoses, hepatitis, nephrotic syndrome, systemic lupus erythematosus and generalized lymphadenopathy.
The term ‘dapsone syndrome’ is applied to a skin rash and fever occurring 2–8 weeks after starting therapy and sometimes accompanied by lymphadenopathy, hepatomegaly, jaundice and/or mononucleosis.
Blood disorders include anemia, methemoglobinemia, sulfhemoglobinemia, hemolysis (notably in patients with glucose- 6-phosphate dehydrogenase deficiency), mononucleosis, leukopenia and, rarely, agranulocytosis. Severe anemia should be treated before patients receive dapsone.
The incidence of adverse reactions declined in the 1960s but reappeared around 1982 when multidrug therapy was introduced, and may represent an unexplained interaction with rifampicin.

Sicherheitsprofil

Poison by ingestion, intraperitoneal, and subcutaneous routes. Human systemic effects by ingestion: agranulocytosis, change in tubules and other kidney changes, cyanosis, effect on joints, hemolysis with or without anemia, jaundice, methemoglobinemiacarboxyhemoglobinemia, retinal changes, somnolence. Experimental reproductive effects. Can cause hepatitis, dermatitis, and neuritis. Questionable carcinogen with experimental carcinogenic and neoplastigenic data. Human mutation data reported. Used in leprosy treatment and veterinary medicine. When heated to decomposition it emits very toxic fumes of NOx and SOx. See also SULFONATES.

4,4'-Diaminodiphenylsulfon Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


4,4'-Diaminodiphenylsulfon Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 336)Lieferanten
Firmenname Telefon Fax E-Mail Land Produktkatalog Edge Rate
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 Abel@chembj.com CHINA 3194 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 21745 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20672 55
Mainchem Co., Ltd.
+86-0592-6210733
+86-0592-6210733 sales@mainchem.com CHINA 32447 55
Yancheng Green Chemicals Co.,Ltd
86-515-87883661
86-515-87883652 sales@greenchem-china.com CHINA 348 58
Hebei Chisure Biotechnology Co., Ltd.
+8613292890173
0311 66567340 luna@speedgainpharma.com CHINA 1017 58
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 27142 58
Hebei Huanhao Biotechnology Co., Ltd.
86-0311-83975816 whatsapp +8618034554576
86-0311-83975816 grace@hbhuanhao.com CHINA 696 58
Chemwill Asia Co.,Ltd.
86-21-51086038
86-21-51861608 chemwill_asia@126.com;sales@chemwill.com;chemwill@hotmail.com;chemwill@gmail.com CHINA 23967 58
Hubei Jusheng Technology Co.,Ltd.
86-18871470254
027-59599243 sales@jushengtech.com CHINA 28236 58

80-08-0(4,4'-Diaminodiphenylsulfon)Verwandte Suche:


  • 4,4’-sulfonylbis-Benzenamine
  • 4,4’-sulfonyldi-anilin
  • 4,4’-sulphonylbisbenzamine
  • 4,4’-sulphonylbisbenzenamine
  • 4,4’-sulphonyldianiline
  • 4,4'-Dapsone
  • 4,4-Diaminodifenylsulfon
  • 4,4'-Dulfonylbisbenzeneamine
  • 4,4'-Sulfonylbis[benzamine]
  • 4,4'-Sulfonylbisaniline
  • p,p’-diaminodiphenylsulfone
  • p,p'-diaminodiphenyl sulfone
  • p,p-Diaminodiphenyl sulphone
  • p,p-diaminodiphenylsulphone
  • p,p-Sulfonylbisbenzamine
  • p,p-Sulfonylbisbenzenamine
  • p,p-Sulphonylbisbenzamine
  • p,p-Sulphonylbisbenzenamine
  • p,p-Sulphonyldianiline
  • Sulfadione
  • Sulfanona-mae
  • Sulfona
  • Sulfone ucb
  • sulfoneucb
  • Sulfon-mere
  • Sulfonyldianiline
  • Sulphon-mere
  • Sulphonyldianiline
  • Sumicure S
  • sumicures
  • Tarimyl
  • Udolac
  • WR 448
  • wr448
  • 4,4μ-Diaminodiphenyl sulfone, 4,4μ-Sulfonyldianiline, 4-Aminophenyl sulfone, Bis(4-aminophenyl) sulfone, Dapsone, DDS
  • 4-[(4-aminophenyl)sulfonyl]aniline
  • (1R,2S,3S,4S)-N,N,N',N'-Tetraethylbicyclo[2.2.1]hept-5-ene-2,3-dicarboxamide
  • Analeptan
  • Euvasculin
  • Vasadol
  • 4-Aminophenyl sulfone,97%
  • 4,4'-Diaminodiphenyl sulfone ,99.5%
  • Dapsone (125 mg)
  • 4,4zzhlxy-Diaminodiphenyl sulfone (Dapsone)
  • Dapsone, USP
  • 4-AMinophenyl sulfone, 97% 100GR
  • 4,4'-Diaminodiphenyl Sulfone 4,4'-Sulfonyldianiline
  • DDS)Dap
  • 4,4- twoaMino twophenyl sulfone
  • 4-AMinophenyl sulfone 97%
  • 4,4'-DiaMinodiphenyl sulfone, 99.5%, 99.5%
  • Dapsone (200 mg)
  • 4,4-DIAMINODIPHENYLSULPHONE4,4-DIAMINODIPHENYLSULPHONE
  • dapsone、diaminodiphenys
  • 4,4- two amino sulfoxide (DDS)
  • 4,4'diaminodiphenylsulfone (4,4'-DDS)
  • 4,4'-Diaminodiphenylsulfon
  • FREE SAMPLE NCV 4,4-DIAMINO DIPHENYL SULPHONE STD
Copyright 2019 © ChemicalBook. All rights reserved